Five-Year Data from RELATIVITY-047 Trial Emphasizes LAG-3 Biomarker Selection in Advanced Melanoma

New five-year data from the phase 3 RELATIVITY-047 trial, published in Nature Medicine, underscores the critical role of LAG-3 biomarker selection in treating advanced melanoma. The study showed a notable survival benefit in patients with high LAG-3 CD8+ T cell expression when treated with relatlimab plus nivolumab, suggesting that biomarker-driven approaches are imperative for optimizing outcomes in this patient population.